Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00144911 · ClinicalTrials.gov registry record · Phase 4
ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies.
A Phase 4 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 4
- Development phase
- 740
- Enrollment target
NCT00144911 is a Phase 4 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 740 participants.
The verdict
NCT00144911, a Phase 4 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 740 participants
- Enrollment target
Study Summary
This study evaluates the effect of two medicines on COPD (Chronic Obstructive Pulmonary Disease) exacerbations. This study will last up to 56 weeks, and subjects will visit the clinic 10 times. Subjects will be given breathing tests and will record their breathing symptoms daily on diary cards. All study related medicines and medical examinations will be provided at no cost. The two drugs used in this study have been approved by the FDA for use in patients with COPD.
Interventions
- DRUG Salmeterol
- DRUG Fluticasone Propionate/Salmeterol Combination Product
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 740 participants |
| Start Date | 2004-10 |
| Est. Completion | 2006-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00144911
The ClinicalTrials.gov registry entry for NCT00144911 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 740 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Salmeterol is the first listed.
NCT00144911 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00144911 about?
NCT00144911 is a clinical study titled "ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies.". This study evaluates the effect of two medicines on COPD (Chronic Obstructive Pulmonary Disease) exacerbations. This study will last up to 56 weeks, and subjects will visit the clinic 10 times. Subjects will be given breathing tests and will record their breathing symptoms daily on diary cards. All ...
What is the current status of trial NCT00144911?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 740 participants. The study started on 2004-10. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00144911?
The interventions under investigation include: Salmeterol (DRUG), Fluticasone Propionate/Salmeterol Combination Product (DRUG).
Who is sponsoring clinical trial NCT00144911?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.